Neurocysticercosis

Therapeutic Advances in Neurological Disorders

Volumn 4, Issue 2, 2011, Pages 67-81

  Singhi, Pratibha ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

cysticidal therapy; epilepsy; neurocysticercosis

Indexed keywords

ALBENDAZOLE; ALBENDAZOLE SULFOXIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CORTICOSTEROID; DEXAMETHASONE; PHENYTOIN; PLACEBO; PRAZIQUANTEL; PREDNISOLONE; STEROID;

ABDOMINAL DISCOMFORT; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANIMAL HUSBANDRY; ANTICONVULSANT THERAPY; ARTHRALGIA; CESTODE LIFE CYCLE STAGE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL (TOPIC); DIAGNOSTIC TEST; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DROWSINESS; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; EDEMA; EPILEPSY; EPILEPTIC STATE; FIRST PASS EFFECT; GASTROINTESTINAL SYMPTOM; GRAY MATTER; HEADACHE; HUMAN; HYDROCEPHALUS; HYGIENE; IMMUNE RESPONSE; INTRACRANIAL HYPERTENSION; JAUNDICE; LEUKOPENIA; MYALGIA; NAUSEA; NEUROCYSTICERCOSIS; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; REVIEW; SANITATION; SEIZURE; SIDE EFFECT; TAENIA SOLIUM; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; URTICARIA; VOMITING; WHITE MATTER;

EID: 79956015093     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285610395654     Document Type: Review

References (94)

1. Abba K. Ramaratnam S. Ranganathan L.N. (2010) Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev 20: CD000215–CD000215.
2. Allan J.C. Velasquez-Tohom M. Fletes C. Torres-Alvarez R. Lopez-Virula G. Yurrita P. et al (1997) Mass chemotherapy for intestinal Taenia solium infection: effect on prevalence in humans and pigs. Trans R Soc Trop Med Hyg 91: 595–598.
3. Alvarez J.I. Rivera J. Teale J.M. (2008) Differential release and phagocytosis of tegument glycoconjugates in neurocysticercosis: implications for immune evasion strategies. PLoS Negl Trop Dis 2: e218–e218, doi:10.1371/Journal Pntd.0000218.
4. Atluri S.R. Singhi P. Khandelwal N. Malla N. (2009) Neurocysticercosis immunodiagnosis using Taenia solium cysticerci crude soluble extract, excretory secretory and lower molecular mass antigens in serum and urine samples of Indian children. Acta Trop 110: 22–27.
5. Baranwal A.K. Singhi P. Singhi S. Khandelwal N. (2001) Seizure recurrence in children with focal seizures and single small enhancing computed tomographic lesions. Prognostic factors on long-term follow-up. J Child Neurol 16: 443–445.
6. Baranwal A.K. Singhi P.D. Khandelwal N. Singhi S.C. (1998) Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized placebo-controlled, double blind trial. Pediatric Infect Dis J 17: 696–700.
7. Bittencourt P.R. Gracia C.M. Martins R. Fernandes A.G. Diekmann H.W. Jung W. (1992) Phenytoin and carbamazepine decrease oral bioavailability of praziquantel. Neurology 42: 492–496.
8. Cárdenas, G., Carrillo-Mezo, R., Jung, H., Sciutto, E., Hernandez, J.L. and Fleury, A. (2010) Subarachnoidal neurocysticercosis non-responsive to cysticidal drugs: a case series. BMC Neurol 10: 16, http://www.biomedcentral.com/1471-2377/10/16.
9. Carpio A. Escobar A. Hauser A.W. (1998) Cysticercosis and epilepsy: a critical review. Epilepsia 39: 1025–1040.
10. Carpio A. Kelvin E.A. Bagiella E. Leslie D. Leon P. Andrews H. et al (2008) Ecuadorian Neurocysticercosis Group. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 79: 1050–1055.
11. Carpio A. Santillan F. Leon P. Flores C. Hauser W.A. (1995) Is the course of neurocysticercosis modified by treatment with antihelminthic agents. Arch Intern Med 155: 1982–1988.
12. Castro N. Márquez-Caraveo C. Brundage R.C. González-Esquivel D. Suárez A.M. Góngora F. et al (2009) Population pharmacokinetics of albendazole in patients with neurocysticercosis. Int J Clin Pharmacol Ther 47: 679–685.
13. Chaurasia R.N. Garg R.K. Agarwall A. Kohli N. Verma R. Singh M.K. et al (2010) Three day albendazole therapy in patients with a solitary cysticercus granuloma: a randomized double blind placebo controlled study. Southeast Asian J Trop Med Public Health 41: 517–525.
14. Commission on Tropical Diseases of the International League Against Epilepsy. (1994) Relationship between epilepsy and tropical diseases. Epilepsia 35: 89–93.
15. Cruz M. Cruz L. Horton J. (1991) Albendazole vs praziquantel in the treatment of cerebral cysticercosis: clinical evaluation. Trans R Soc Trop Med Hyg 85: 244–247.
16. Cruz M. Davis A. Dixon H. Pawlowski Z.S. Proano J. (1989) Operational studies on the control of Taenia solium taeniasis / cysticercosis in Ecuador. Bull World Health Organ 67: 401–407.
17. Das K. Mondal G.P. Banerjee M. Mukherjee B.B. Singh O.P. (2007) Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study. J Clin Neurosci 14: 1172–1177.
18. de Souza A. Nalini A. Kovoor J.M. Yeshraj G. Siddalingaiah H.S. Thennarasu K. (2010) Natural history of solitary cerebral cysticercosis on serial magnetic resonance imaging and the effect of albendazole therapy on its evolution. J Neurol Sci 288: 135–141.
19. Del Brutto O.H. (1994) Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis. Neurology 44: 1706–1709.
20. Del Brutto O.H. (1995) Medical treatment of cysticercosis – effective. Arch Neurol 52: 102–104.
21. Del Brutto O.H. (1997) Is the course of neurocysticercosis modified by treatment with anthelmintic agents? Arch Intern Med 157: 128–130.
22. Del Brutto O.H. Rajshekhar V. White A.C. J Tsang V.C. Nash T.E. Takayanagui O.M. et al (2001) Proposed diagnostic criteria for neurocysticercosis. Neurology 57: 177–183.
23. Del Brutto O.H. Roos K.L. Coffey C.S. García H.H. (2006) Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med 145: 43–51.
24. Del Brutto O.H. Santibanez R. Noboa C.A. Aguirre R. Diaz E. Alarcon T.A. (1992) Epilepsy due to neurocysticercosis analysis of 203 patients. Neurology 42: 389–392.
25. Escobar A. (1983) The pathology of neurocysticercosis. In: Ed. Palacios E. Rodriguez-Carbajal K.J. Taveras J. (eds), Cysticercosis of the central nervous system, Charles C. Thomas: Springfield, IL, 27–54.
26. Escobedo F. Penagos P. Rodriquez J. Sotelo J. (1987) Albendazole therapy for neurocysticercosis. Arch Intern Med 147: 738–741.
27. Fleury A. Escobar A. Fragoso G. Sciutto E. Larralde C. (2010) Clinical heterogeneity of human neurocysticercosis results from complex interactions among parasite, host and environmental factors. Trans R Soc Trop Med Hyg 104: 243–250.
28. Fleury A. Morales J. Bobes R.J. Dumas M. Yanez O. Pina J. et al (2006) An epidemiological study of familial neurocysticercosis in an endemic Mexican community. Trans R Soc Trop Med Hyg 100: 551–558.
29. Garcia H.H. (2008) Antiparasitic drugs in neurocysticercosis: albendazole or praziquantel? Expert Rev Anti Infect Ther 6: 295–298.
30. García H.H. Evans C.A. Nash T.E. Takayanagui O.M. White A.C. Jr Botero D. et al (2002) Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 15: 747–756.
31. Garcia H.H. Gonzalez A.E. Gilman R.H. (2003) The Cysticercosis Working Group in Peru. Diagnosis, treatment and control of Taenia solium cysticercosis. Curr Opin Infect Dis 16: 411–419.
32. Garcia H.H. Gonzalez A.E. Gilman R.H. Moulton L.H. Verastegui M. Rodriguez S. et al (2006) Cysticercosis Working Group in Peru. Combined human and porcine mass chemotherapy for the control of T. solium. Am J Trop Med Hyg 74: 850–855.
33. Garcia H.H. Pretell E.J. Gilman R.H. Martinez S.M. Moulton L.H. Del Brutto O.H. et al (2004) Cysticercosis Working Group in Peru. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 350: 249–258.
34. Goel D. Mittal M. Bansal K.K. Singhal A. (2010) Natural history of solitary cerebral cysticercosis cases after albendazole therapy: a longitudinal follow-up study from India. Acta Neurol Scand 121: 204–208.
35. Goel R.K. Ahmad F.U. Vellimana A.K. Suri A. Chandra P.S. Kumar R. et al (2008) Endoscopic management of intraventricular neurocysticercosis. J Clin Neurosci 15: 1096–1101.
36. Govindappa S.S. Narayanan J.P. Krishnamoorthy V.M. Shastry C.H. Balasurbramaniam A. Krishna S.S. et al (2000) Improved detection of Intraventricular cysticeral cysts with the use of three-dimensional constructive interference in steady state MR sequences. AJNR Am J Neuroradiol 21: 679–684.
37. Gupta R.K. Prakash M. Mishra A.M. Husain M. Prasad K.N. Husain N. et al (2005) Role of diffusion weighted imaging in differentiation of intracranial tuberculoma and tuberculous abscess from cysticercus granulomas-a report of more than 100 lesions. Eur J Radiol 55: 384–392.
38. Hell R.C. Amim P. de Andrade H.M. de Avila R.A. Felicori L. Oliveira A.G. et al (2009) Immunodiagnosis of human neurocysticercosis using a synthetic peptide selected by phage-display. Clin Immunol 131: 129–138.
39. Jain S. Padma M.V. Kanga U. Mehra N.K. Maheshwari N.C. (1999) Family studies and human leukocyte antigen class II typing in Indian probands with seizures in association with single small enhancing computed tomography lesions. Epilepsia 40: 232–238.
40. Jung H. Hurtado M. Medina M.T. Sanchez M. Sotelo J. (1990) Dexamethasone increases plasma levels of albendazole. J Neurol 237: 279–280.
41. Kalra V. Dua T. Kumar V. (2003) Efficacy of albendazole and short-course dexamethasone treatment in children with 1 or 2 ring-enhancing lesions of neurocysticercosis: a randomized controlled trial. J Pediatr 143: 111–114.
42. Kathuria M.K. Gupta R.K. Roy R. Gaur V. Husain N. Pradhan S. (1998) Measurement of magnetization transfer in different stages of neurocysticercosis. J Magn Reson Imaging 8: 473–479.
43. Kaur S. Singhi P. Singhi S. Khandelwal N. (2009) Combination therapy of praziquantel and albendazole versus albendazole alone in children with single lesion NCC–a randomized placebo controlled double blind trial. Ped Infect Dis J 28: 403–406.
44. Kelvin E.A. Carpio A. Hesdorffer D.C. Bagiella E. Leslie D. Leon P. et al (2009) Investigation of familial aggregation of seizures in neurocysticercosis patients. Epilepsy Res 84: 67–71.
45. Kishore D. Misra S. (2007) Short course of oral prednisolone on disappearance of lesion and seizure recurrence in patients of solitary cysticercal granuloma with single small enhancing CT lesion: an open label randomized prospective study. J Assoc Physicians India 55: 419–424.
46. Kramer L.D. (1995) Medical treatment of cysticercosis – ineffective. Arch Neurol 52: 101–102.
47. Lightowlers M.W. (2010) Eradication of Taenia solium cysticercosis: a role for vaccination of pigs. Int J Parasitol 40: 1183–1192.
48. Mahanty S. Garcia H.H. (2010) Cysticercosis Working Group in Perú. Cysticercosis and neurocysticercosis as pathogens affecting the nervous system. Prog Neurobiol 91: 172–184.
49. Mall R.K. Agarwal A. Garg R.K. Kar A.M. Shukla R. (2003) Short course of prednisolone in Indian patients with solitary cysticercus granuloma and new-onset seizures. Epilepsia 44: 1397–1401.
50. Mandal J. Singhi P.D. Khandelwal N. Malla N. (2006) Evaluation of ELISA and dot blots for the serodiagnosis of neurocysticercosis, in children found to have single or multiple enhancing lesions in computerized tomographic scans of the brain. Ann Trop Med Parasitol 100: 39–48.
51. Maravilla P. Gonzalez-Guzman R. Zuniga G. Peniche A. Dominguez-Alpizar J.L. Reyes-Montes R. et al (2008) Genetic polymorphism in Taenia solium cysticerci recovered from experimental infections in pigs. Infect Genet Evol 8: 213–216.
52. Medina M.T. Genton P. Montoya M.C. Cordova S. Dravet C. Sotelo J. et al (1993) Effect of anticysticercal treatment on the prognosis of epilepsy in neurocysticercosis: A pilot trial. Epilepsia 34: 1024–1027.
53. Morales N.M. Agapejev S. Morales R.R. Padula N.A. Lima M.M. (2000) Clinical aspects of neurocysticercosis in children. Pediatr Neurol 22: 287–291.
54. Nash T.E. Pretell J. Garcia H.H. (2001) Calcified cysticerci provoke perilesional edema and seizures. Clin Infect Dis 33: 1649–1653.
55. Nash T.E. Singh G. White A.G. Rajshekhar V. Loeb J.A. Proaño J.V. et al (2006) Treatment of neurocysticercosis: current status and future research needs. Neurology 67: 1120–1127.
56. Padma M.V. Behari M. Misra N.K. Ahuja G.K. (1994) Albendazole in single CT ring lesions in epilepsy. Neurology 44: 1344–1346.
57. Pretell E.J. Garcia H.H. Custodio N. Padilla C. Alvarado M. Gilman R.H. et al (2000) Short regimen of praziquantel in the treatment of single brain enhancing lesions. Clin Neurol Neurosurg 102: 215–218.
58. Pretell E.J. Garcia H.H. Gilman R.H. Saavedra H. Martinez M. (2001) The Cysticercosis Working Group in Peru. Failure of one-day praziquantel treatment in patients with multiple neurocysticercosis lesions. Clin Neurol Neurosurg 103: 175–177.
59. Pretell E.J. Martinot C. Jr Garcia H.H. Alvarado M. Bustos J.A. Martinot C. (2005) Cysticercosis Working Group in Peru. Differential diagnosis between cerebral tuberculosis and neurocysticercosis by magnetic resonance spectroscopy. J Comput Assist Tomogr 1: 112–114.
60. Proaño J.V. Madrazo I. Avelar F. López-Félix B. Díaz G. Grijalva I. et al (2001) Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med 345: 879–885.
61. Raffin L.S. Bacheschi L.A. Machado L.R. Nobrega J.P.S. Coelho C. Leite C.C. (2001) Diffusion-weighted MR imaging of cystic lesions of neurocysticercosis. Arq Neuropsiquiatr 59: 839–842.
62. Rajshekhar V. Haran R.P. Prakash S. Chandy M.J. (1993) Differentiating solitary small cysticercus granulomas and tuberculomas in patients with epilepsy–clinical and computerized tomographic criteria. J Neurosurgery 78: 402–407.
63. Robbani I. Razdan S. Pandita K.K. (2004) Diagnosis of intraventricular cysticercosis by magnetic resonance imaging: improved detection with three-dimensional spoiled gradient recalled echo sequences. Australas Radiol 48: 237–239.
64. Rodriguez S. Dorny P. Tsang V.C. Pretell E.J. Brandt J. Lescano A.G. et al (2009) Cysticercosis Working Group in Peru. Detection of Taenia solium antigens and anti-T. solium antibodies in paired serum and cerebrospinal fluid samples from patients with intraparenchymal or extraparenchymal neurocysticercosis. J Infect Dis 199: 1345–1352.
65. Rodriguez-Sosa M. Satoskar A.R. Calderon R. Gomez-Garcia L. Saavedra R. Bojalil R. et al (2002) Chronic helminth infection induces alternatively activated macrophages expressing high levels of CCR 5 with low interleukin-12 production and TH2-biasing ability. Infect Immun 70: 3656–3664.
66. Román G. Sotelo J. Del Brutto O. Flisser A. Dumas M. Wadia N. et al (2000) A proposal to declare neurocysticercosis an international reportable disease. Bull World Health Organ 78: 399–406.
67. Saenz B. Ruiz-Garcia M. Jimenez E. Hernandez-Aguilar J. Suastegui R. Larralde C. et al (2006) Neurocysticercosis: clinical, radiologic, and inflammatory differences between children and adults. Pediatr Infect Dis J 25: 801–803.
68. Sahu P.S. Parija S.C. Jayachandran S. (2010) Antibody specific to 43kDa excretory-secretory antigenic peptide of Taenia solium metacestode as a potential diagnostic marker in human neurocysticercosis. Acta Trop 115: 257–261.
69. Sahu P.S. Parija S.C. Narayan S.K. Kumar D. (2009) Evaluation of an IgG-ELISA strategy using Taenia solium metacestode somatic and excretory-secretory antigens for diagnosis of neurocysticercosis revealing biological stage of the larvae. Acta Trop 110: 38–45.
70. Salinas R. Counsell C. Prasad K. Gelband H. Garner P. (1999) Treating neurocysticercosis medically: a systematic review of randomized, controlled trials. Trop Med Int Health 4: 713–718.
71. Salinas R. Prasad K. (2007) Drugs for treating neurocysticercosis (tapeworm infection of the brain). Cochrane Database Syst Rev 18: CD000215–CD000215.
72. Sarti E. Schantz P.M. Avila G. Ambrosio J. Medina-Santillan R. Flisser A. (2000) Mass treatment against human taeniasis for the control of cysticercosis: a population based intervention study. Trans R Soc Trop Med Hyg 94: 85–89.
73. Singh G. (1997) Neurocysticercosis in South–Central America and the Indian subcontinent. A comparative evaluation. Arq Neuropsiquiatr 55: 349–356.
74. Singhi P. Dayal D. Khandelwal N. (2003 a) One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized placebo controlled double blind trial. Pediatr Infect Dis J 22: 268–272.
75. Singhi P. Dinakaran Khandelwal N.K. (2003 b) One year versus two years of antiepileptic therapy for SSECTL. J Trop Pediatr 5: 274–278.
76. Singhi P. Jain V. Khandelwal N. (2004) Corticosteroids versus albendazole for treatment of single small enhancing CT lesions in children with NCC. J Child Neurol 19: 323–327.
77. Singhi P. Mahajan V. Khandelwal N. (2008) Sudden-onset ptosis caused by midbrain neurocysticercosis in two children. J Child Neurol 3: 334–337.
78. Singhi P. Ray M. Singhi S. Khandelwal N. (2000) Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy. J Child Neurol 15: 207–213.
79. Singhi P.D. Baranwal A.K. (2001) Single small enhancing computed tomographic lesion in Indian children–I: Evolution of current concepts. J Trop Pediatr 47: 204–207.
80. Sotelo J. del Brutto O.H. Penagos P. Escobedo F. Torres B. Rodriguez-Carbajal J. et al (1990) Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J Neurol 237: 69–72.
81. Sotelo J. Escobedo F. Rodriguez-Carbajal J. Torres B. Rubio-Donnadieu F. (1984) Therapy of parenchymal brain cysticercosis with praziquantel. N Engl J Med 310: 1001–1007.
82. Sotelo J. Guerrero V. Rubio F. (1985 a) Neurocysticercosis: A new classification based on active and inactive forms. A study of 753 cases. Arch Intern Med 145: 442–445.
83. Sotelo J. Torres B. Rubio-Donnadieu F. Escobedo F. Rodriquez-Carbajal J. (1985 b) Praziquantel in the treatment of neurocysticercosis: long term follow-up. Neurology 35: 752–755.
84. Suri A. Goel R.K. Ahmad F.U. Vellimana A.K. Sharma B.S. Mahapatra A.K. et al (2008) Transventricular, transaqueductal scope-in-scope endoscopic excision of fourth ventricular neurocysticercosis: a series of 13 cases and a review. J Neurosurg Pediatr 1: 35–39.
85. Takayanagui O.M. Jardim E. (1992) Therapy for neurocysticercosis. Comparison between albendazole and praziquantel. Arch Neurol 49: 290–294.
86. Talukdar B. Saxena A. Popli V.K. Choudhury V. (2002) Neurocysticercosis in children: clinical characteristics and outcome. Ann Trop Pediatr 22: 333–339.
87. Thussu A. Chattopadhyay A. Sawhney I.M. Khandelwal N. (2008) Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy. J Neurol Neurosurg Psychiatry 79: 238–239.
88. Tsang V.C. Brand J.A. Boyer A.E. (1989) An enzyme-linked immunoelectro-transfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium). J Infect Dis 159: 50–59.
89. Vazquez M.L. Jung H. Sotelo J. (1987) Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. Neurology 37: 1561–1562.
90. Vazquez V. Sotelo J. (1992) The course of seizures after treatment for cerebral cysticercosis. N Engl J Med 327: 696–701.
91. Vega R. Pinero D. Ramanankandrasana B. Dumas M. Bouteille B. Fleury A. et al (2003) Population genetic structure of Taenia solium from Madagascar and Mexico: implications for clinical profile diversity and immunological technology. Int J Parasitol 33: 1479–1485.
92. Verma, A., Prasad, K.N., Gupta, R.K., Singh, A.K., Nyati, K.K., Rizwan, A. et al. (2010) Toll-like receptor 4 polymorphism and its association with symptomatic neurocysticercosis. J Infect Dis 202: 1219–1225.
93. White A.C. Jr (1997) Neurocysticercosis: a major cause of neurological disease worldwide. Clin Infect Dis 24: 101–113.
94. White A.C. Jr Robinson P. Kuhn R. (1997) Taenia solium cysitcercosis host–parasite interactions and the immune response. Chem Immunol 66: 209–230.